Related Scientific Literature
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho
- Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho
- Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape
- Detection of COVID-19: A review of the current literature and future perspectives
- Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
- RT-PCR testing to detect a COVID-19 outbreak in Austria: rapid, accurate and early diagnosis in primary care (The REAP study)
- Correlation of ELISA based with random access serologic immunoassays for identifying adaptive immune response to SARS-CoV-2
- EVALUATION OF THE ABBOTT SARS-COV-2 IG-G ASSAY
- Current and Perspective Diagnostic Techniques for COVID-19
- SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department
- Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)
- Molecular and Immunological Diagnostic Tests of COVID-19: Current Status and Challenges
- Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
- In vitro diagnostics of coronavirus disease 2019: Technologies and application
- Performance characteristics of four high-throughput immunoassays for detection of igg antibodies against sars-cov-2
- Testing For SARS-CoV-2: The Day the World Turned its Attention to the Clinical Laboratory
- How should diagnostic kits development adapt quickly in COVID 19-like pandemic models? Pros and cons of sensory platforms used in COVID-19 sensing
- Validation and performance comparison of three SARS-CoV-2 antibody assays
- Comparison of different serological assays for SARS-CoV-2 in real life
- Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays
- Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients
- Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV
- Trends and Innovations in Biosensors for COVID-19 Mass Testing
- Review of Current Advances in Serologic Testing for COVID-19
- Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test
- Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology
- Method comparison of SARS-CoV-2 serology assays involving three commercially available platforms and a novel in-house developed enzyme-linked immunosorbent assay
- Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
- Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation
- Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - the CoNAN study
- Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies
- Comparison of various serological assays for novel SARS-COV-2
- Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection
- Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs
- Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests
- Kinetics and performance of the Abbott Architect SARS-CoV-2 IgG antibody assay
- Clinical Performance of Two SARS-CoV-2 Serologic Assays
- Evaluation of Three Commercial Automated Assays for the Detection of anti-SARS-CoV-2 Antibodies
- Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
- Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA Assay for Detecting SARS-CoV-2 IgG
- Multi-platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19
- Evaluation of six commercial mid to high volume antibody and six point of care lateral flow assays for detection of SARS-CoV-2 antibodies
- High-throughput immunoassays for SARS-CoV-2 – considerable differences in performance when comparing three methods
- Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent sera
- Comparison of sixteen serological SARS-CoV-2 immunoassays in sixteen clinical laboratories
- Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents
- Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with
- Overcoming Supply Shortage for SARS-CoV-2 Detection by RT-qPCR.
- Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech.
- Performance of SARS-CoV-2 serology tests: Are they good enough?
- Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing.
- Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection.
- In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.